Please assess the completion status of the following clinical trial:

Trial Title: Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Each patient must meet all of the following inclusion criteria to be enrolled in the study.~* Males or non-pregnant, non-lactating females voluntarily able to give informed consent~* All patients must agree to use 2 effective forms of contraception from screening to the end of the study~* Negative surveillance colonoscopy within the last 6 months if indicated by standard clinical practice guidelines~* Confirmed and active ulcerative colitis (UC)~  * Partial Mayo Score 1 - 7~ * Disease involvement extending proximal to the rectum~* May be receiving a therapeutic dose of conventional therapies for UC as defined by the protocol~Exclusion Criteria:~Patients meeting any of the following exclusion criteria are not to be enrolled in the study.~* Patients who require ulcerative colitis (UC) surgical intervention or for whom surgical intervention is anticipated during the study~* Patients who fail to meet laboratory values as specified in the protocol or have a positive progressive multifocal leukoencephalopathy (PML) subjective symptom checklist during the screening period~* Low-grade dysplasia, high-grade dysplasia, dysplasia-associated lesion or mass, or colorectal cancer~* Treatment with cyclosporine, FK506 (tacrolimus) or infliximab within 60 days prior to study~* Patients receiving any of the following within 14-days prior to the study: antibiotics for treatment of irritable bowel syndrome, heparin or warfarin, narcotics, tube feeding, defined formula diets or parenteral alimentation~* Colostomy, fistulae or known fixed symptomatic stenosis of the intestine~* Immunologic or ischemic intestinal condition~* Toxic megacolon~* Chronic hepatitis B or C or human immunodeficiency virus (HIV) infection~* Any vaccinations within 30 days prior to study drug administration~* History of imaging abnormalities, multiple sclerosis (MS), brain tumor or neurodegenerative disease~* Significantly impaired liver or renal function~* Current or recent history of alcohol dependence~* Current use of illicit drugs~* Active or recent serious infections or serious underlying disease as specified in protocol~* Active psychiatric problems that might interfere with compliance to study~* Previous exposure to MLN0002~* Participated in an investigational study within 30 days prior to study drug administration or received treatment with an investigational monoclonal antibody within the last 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Vedolizumab-matching placebo, intravenous (IV), infusion on Days 1, 15, 29 and 85.
- Vedolizumab 2 mg/kg (Type: EXPERIMENTAL): Vedolizumab, 2 mg/kg, IV infusion on Days 1, 15, 29 and 85.
- Vedolizumab 6 mg/kg (Type: EXPERIMENTAL): Vedolizumab 6 mg/kg, IV infusion on Days 1, 15, 29 and 85.
- Vedolizumab 10 mg/kg (Type: EXPERIMENTAL): Vedolizumab 10 mg/kg, IV infusion on Days 1, 15, 29 and 85.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete